On the impact of surveillance test strategies: a cost-benefit modelling analysis based upon real-world data from SARS-CoV-2.


Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 06 09 2023
revised: 20 12 2023
accepted: 21 12 2023
medline: 18 3 2024
pubmed: 21 1 2024
entrez: 20 1 2024
Statut: ppublish

Résumé

Active regular surveillance testing of asymptomatic and symptomatic individuals can reduce infection and onward transmission rates, as demonstrated for SARS-CoV-2. Cost-benefit analysis based on real-world data. Two different surveillance-testing strategies using nucleic acid amplification tests (NAATs) performed in 14,177 hospital employees were compared for their costs and their effectiveness in preventing secondary infections. Compared to not testing, NAAT-based testing twice a week accompanied by contact tracing or testing five times a week without tracing of contacts were more effective in preventing infections through early identification of infected individuals. While expansion of the test frequency from two to five times per week increased the initial costs, importantly, a 49.6 % higher inhibitory effect on infection growth with a 11.1-fold reduction of potentially averted infections and resulting workforce loss was observed, demonstrating a substantial cost-benefit of the 5-tests-per-week strategy. Adaptation of the test frequency of SARS-CoV-2 and possibly of other pathogens with epidemic potential according to the prevailing incidences and reproduction rates in high-prevalence situations may not only be beneficial in averting potential infections in hospital employees and, subsequently, on a population level but may also represent the most cost-effective method.

Identifiants

pubmed: 38244316
pii: S0033-3506(23)00506-1
doi: 10.1016/j.puhe.2023.12.027
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

T Spath (T)

University Hospital Vienna, Directorate of Nursing Services, Vienna, Austria; Medical University of Vienna, Department of Dermatology, Vienna, Austria.

M Kundi (M)

Medical University of Vienna, Center of Public Health, Department for Environmental Health, Vienna, Austria.

R Strassl (R)

Medical University of Vienna, Department of Laboratory Medicine, Division of Clinical Virology, Vienna, Austria.

G Kornek (G)

University Hospital Vienna, Medical Directorate, Vienna, Austria.

H Wetzlinger (H)

University Hospital Vienna, Directorate, Vienna, Austria.

F Thalhammer (F)

Medical University of Vienna, Department of Urology, Vienna, Austria.

A Handisurya (A)

Medical University of Vienna, Department of Dermatology, Vienna, Austria. Electronic address: alessandra.handisurya@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH